Anatara announces Australian patent granted for GaRP candidate

Latest News

Anatara Lifesciences (ASX:ANR) has reported that it has received certification of the grant of a standard patent on 23 January for the GaRP product under the invention title of 'Gastrointestinal Health Composition'.

The patent numbered 2020364192 was granted by the Commissioner of Patents for the Australian Patent Office and has a term of 20 years from 9 October 2020.

This follows a European patent grant from the European Patent Office for the title and documents relating to its Gastrointestinal ReProgramming product (GaRP).

Anatara’s executive chair, Dr David Brookes, said, “This patent grant is further confirmation of the uniqueness of GaRP and consolidates the commercial proposition. The mechanism of action of GaRP is based on ingredients designed to restore and maintain the gastrointestinal tract lining and dynamics, using sophisticated coatings and combinations. This potentially has broad health indications and we look forward to the progress of our current Phase II GaRP-IBS trial in establishing efficacy data. A successful conclusion of the Irritable Bowel Syndrome (IBS) clinical trial is obviously a key consideration for market differentiation and commercialisation.”

Anatara said GaRP is expected to be applicable to a wide range of indications in gastrointestinal health beyond IBS.